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ReviewGlossary
DOPA-responsive dystonia (DRD): a form of dystonia caused by DA deficiency
that is effectively treated by L-DOPA administration.
Dystonia: the symptom of abnormal involuntary twisting movements or
sustained postures caused by coactivation of agonist and antagonist muscle
groups.Primary dystonia is a poorly understood but common
movement disorder. Recently, several new primary dys-
tonia genes were identified that provide new insight into
dystonia pathogenesis. The GNAL dystonia gene is cen-
tral for striatal responses to dopamine (DA) and is a
component of a molecular pathway already implicated
in DOPA-responsive dystonia (DRD). Furthermore, this
pathway is also dysfunctional and pathogenically linked
to mTOR signaling in L-DOPA-induced dyskinesias (LID).
These new data suggest that striatal DA responses are
central to primary dystonia, even when symptoms do
not benefit from DA therapies. Here we integrate these
new findings with current understanding of striatal mi-
crocircuitry and other dystonia-causing insults to devel-
op new ideas on the pathophysiology of this
incapacitating movement disorder.
Dystonia genetics return to DA
Movement is central to human behavior, and the neuro-
logical diseases that affect motor function are severely
incapacitating and a major clinical problem. Primary dys-
tonia (see Glossary) is the third most common neurological
movement disorder. It is characterized by involuntary
muscle contractions that force the body into abnormal
twisted positions and postures or cause patterned or ste-
reotyped movements. Primary dystonia occurs from a nor-
mally appearing CNS and lacks an identifiable structural
or biochemical cause. This disease has higher frequency
amongst individuals who undertake intensive, long-term
motor repetitions to enhance their fine motor skills, such as
musicians [1]. This relationship associates dystonia with
plasticity or over-training of the motor circuits. In addition,
the lack of a gross pathological correlate also supports the
theory that primary dystonia is a functional disease of
abnormal neurochemistry, wiring, or physiology. However,
there is no consistent neuropharmacological modification0166-2236/$ – see front matter
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biological defects are largely unknown [2–4].
It is also clear that genetics influence the development of
dystonia. Several monogenic familial dystonias have been
identified, and these provide an unbiased route into un-
derstanding the mechanisms of a disease where classical
pharmacological and pathological studies largely fail to
provide insight. The process from gene identification to
mechanistic understanding of dystonia has nevertheless
been slow, in particular because the first primary dystonia
genes are widely expressed and of unknown function.
However, the advent of next-generation sequencing has
increased the speed of dystonia gene discovery. Interest-
ingly, two newly identified primary dystonia genes encode
proteins with relatively specific expression in the striatal
neurons that respond to DA signaling. One of these, GNAL
[guanine nucleotide binding protein (G protein), alpha
activating activity polypeptide, olfactory type], encodes a
postsynaptic element of the same signaling cascade al-
ready implicated in DRD, despite DRD being classically
regarded as mechanistically distinct from primary dysto-
nia. Furthermore, there is also overlap between this dys-
tonia-associated genetic pathway and the molecular
cascade associated with LID and neuroleptic induced dys-
kinesias/dystonias. Considered together, the new genetic
information on primary dystonia and molecular mecha-
nisms of hyperkinetic movement disorders suggests that
overlapping and converging mechanisms may underlie
distinct types of functional dystonias and other hyperki-
netic movement disorders.GNAL/Ga(olf): selectively expressed paralog of widely expressed GNAS/Gas
stimulatory G protein a subunit. Couples excitatory G-protein-coupled
receptors (GPCR) to adenylate cyclase (AC) activation.
L-DOPA (L-3,4-dihydroxyphenylalanine): metabolic precursor to dopamine
(DA) that is used therapeutically to elevate dopamine levels for bradykinesia
in Parkinson’s disease (PD) or DOPA-responsive dystonia.
L-DOPA-induced dyskinesias (LID): side effect of L-DOPA treatment in PD
where L-DOPA fails to stably control motor symptoms and instead induces
motor fluctuations, most commonly hyperkinetic dyskinesias.
Primary dystonia: neurological motor disease where dystonia occurs without a
structural, degenerative, or metabolic explanation.
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The symptom of abnormal twisting movements, dystonia,
occurs within a variety of syndromes. However, many
individuals develop dystonia where there is no identifiable
cause or etiology to explain the movement disorder. There
is no cure for primary dystonia, and most patients are
treated by peripheral administration of Botulinum toxin,
to prevent muscle hyperactivation, or deep brain stimula-
tion (DBS) that modifies basal ganglia rhythmicity via
electrodes implanted into the globus pallidus. However,
DBS is variably effective and addressing which locus is the
primary defect in primary dystonia has been a contentious
issue for decades. At face value, the hyperkinetic nature of
dystonia is similar to dyskinesias or choreas associated
with striatal dysfunction, but primary dystonia lacks the
neurochemical or pathological hallmarks of these condi-
tions. In recent years the idea of primary dystonia as a
network disorder has developed, and focus has turned to
other brain regions such as the cerebellum and the multi-
locus hit hypothesis to explain the symptoms [2,5–12].
Primary dystonia is also a heterogeneous condition.
Symptoms can develop in children or adults. Symptoms
can affect a single body part and only when performing
specific movements, or be generalized, affecting multiple
body segments and lack task-specificity. Interestingly,
symptom variability seems to be a fundamental feature
of dystonia rather than a failure to recognize a spectrum of
different diseases. Even well-defined monogenic primary
dystonias are semi-penetrant and variable in age of onset,
focal or generalized symptoms, or may spread from focal to
generalized dystonia in the course of disease progression.
This consistent variability in primary dystonia is sugges-
tive of a common underlying mechanism, but one that is
plastic and sensitive to multiple genetic or environmental
modifiers that synergize or cancel out to drive or inhibit
symptom development. Here we describe the expected
neurobiological consequences of several dystonia-causing
genetic mutations and integrate this information with new
progress in research into other hyperactive movement
disorders. However, a comprehensive review of all dysto-
nia-causing mutations is beyond the scope of this paper
and we refer the reader to reviews by Ozelius et al. [2] and
Petrucci and Valente [13] for excellent recent descriptions.
Genetic causes of dystonia
TOR1A dystonia is a 30% penetrant, autosomal dominant,
early-onset primary torsion dystonia. The disease-causing
mutation is an in-frame 3 bp deletion in TOR1A (torsin
family 1, member A) and was the first identified primary
dystonia mutation [14]. This deletion impairs TOR1A
activity but also produces a mutant protein that lacks a
single glutamic acid residue that potentially has gain-of-
function or dominant negative actions [15]. TOR1A dysto-
nia symptoms often begin in a single limb and tend to
generalize throughout the body, although there are
instances where the TOR1A mutation produces focal dys-
tonia [16]. The modifiers that underlie incomplete pene-
trance and symptom variability are unknown, but a
complex set of risks and suppressers are hypothesized
because there is no simple link between penetrance and
a genetic locus or environmental trigger. In 2008, THAP1718(thanatos-associated domain-containing apoptosis-associ-
ated protein 1) was discovered as the second primary
dystonia gene. THAP1 dystonia is also autosomal domi-
nant primary dystonia with reduced penetrance and mixed
symptom severity [17]. The cellular roles of torsinA and
THAP1 remain largely unknown, and these are broadly
expressed proteins that have not yet led to cellular or
neurobiological explanations for primary dystonia.
L-DOPA is a DA replacement therapy that causes dra-
matic, rapid improvement of DRD. This type of dystonia is
classically regarded as a neurometabolic disorder and
mechanistically distinct to forms of primary dystonia that
otherwise are known to fail to respond to DA drugs [18].
However, similarly to TOR1A and THAP1 dystonias, DRD
is early onset, with reduced penetrance, and the symptoms
often spread from a single limb to generalized dystonia.
Pertinently, DRD also represents a situation where dysto-
nia occurs despite normal brain structure. Most DRD is
caused by dominant inheritance of GCH1 (GTP cyclohy-
drolase 1) mutations [18,19]. There are over 100 distinct
pathogenic missense, nonsense, deletions, or splicing
GCH1 mutations, and it therefore appears that GCH1
haploinsufficiency is sufficient to cause DRD. There are
also less frequent recessive forms of DRD caused by muta-
tions in TH (tyrosine hydroxylase) or SPR (sepiapterin
reductase). All three DRD genes participate in DA biosyn-
thesis (Figure 1A): GCH1 and SPR act sequentially to
synthesize tetrahydrobiopterin (BH4), and BH4 is subse-
quently required for TH to synthesize L-DOPA from tyro-
sine [18,20]. Thus, these genetic data strongly associate
depressed striatal DA release with the development of
dystonia.
The advent of next-generation sequencing has rapidly
increased the rate of dystonia gene discovery. Dominantly
inherited mutations that segregate with primary dystonia
are now identified in CIZ1 [CDKN1A (Cip1) interacting
zinc finger protein 1], ANO3 (anoctamine3), TUBB4 (b-
tubulin 4A), and GNAL [21–25]. These recent discoveries
are especially interesting because both ANO3 and GNAL
are enriched in the striatum, the same nucleus affected by
the DRD genetic deficiencies.
ANO3 is a member of the anoctamine gene family whose
best-characterized members are epithelial chloride chan-
nels [26]. Thus, it is possible that ANO3 mutations cause
dystonia by directly perturbing intrinsic neuronal physiol-
ogy, and that the striatum is particularly affected by virtue
of higher ANO3 expression. The GNAL protein is Ga(olf), a
stimulatory a subunit for heterotrimeric G-protein com-
plexes (guanine nucleotide-binding protein). GNAL/Ga(olf)
is a paralog of the widely expressed GNAS gene that
encodes Ga(s). Ga(olf) or Ga(s) both functionally couple
seven transmembrane G-protein-coupled receptors (GPCR)
to adenylate cyclase (AC), and this activity is required for
GPCR-stimulated cAMP production (Figure 1A). GNAS/
Ga(s) is the predominant stimulatory a-subunit in the
CNS and is highly expressed throughout cortex, midbrain,
cerebellum, and brainstem, whereas GNAL/Ga(olf) is
expressed at lower levels and displays a more selective
expression pattern. However, the relative expression of
Ga(s) and Ga(olf) is specifically reversed in the striatum,
where Ga(s) is virtually absent and Ga(olf) mRNA is higher
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Figure 1. A dystonia-associated striatal signaling cascade. (A) Dystonia-causing loss-of-function mutations (yellow stars) in GCH1 (GTP cyclohydrolase 1), TH (tyrosine
hydroxylase) [18,19], and GNAL/Ga(olf) [22] intersect to suppress striatal dopamine (DA) signaling to adenylate cyclase (AC), cAMP, and protein kinase A (PKA). GCH1 and
TH (red) are presynaptic in the terminals of nigrostriatal projection neurons where they participate in DA biosynthesis. There are two classes of DA receptor, D1DR-like (‘D1’
– D1DR and D5DR) and D2DR-like (‘D2’ – D2DR, D3DR, and D4DR) that mediate postsynaptic DA responses. The D1DR and D2DR genes are highly expressed by medium
spiny neurons (MSN) of the direct and indirect pathways, respectively, although other DA receptor genes are more broadly expressed. Striatal D1DR-like receptors are
excitatory and interact with GNAL/Ga(olf) (turquoise) to activate AC. Striatal adenosine 2A receptors (A2A) are specifically expressed by D2DR-bearing MSN, and also
couple to GNAL/Ga(olf) and cAMP production. The inhibitory class of DA receptors, D2DR-like, instead interact with Ga(i)- or Ga(o)-containing G proteins that inhibit cAMP
production, among other targets. Therefore, D1DR-like and A2AR activation have the opposite action to D2DR-like, although the receptors do not necessarily directly
compete and there is evidence for extra complexity due to receptor dimerization [39,40]. The downstream targets of striatal PKA activation are varied, but many PKA-
mediated effects require phosphorylation of the DARPP-32 protein and post-translational modification of receptors, ion channels, and altered gene transcription [67]. The
activation of extracellular signal-regulated kinases 1/2 (ERK1/2) is also a well-characterized response to PKA activation in MSN. Furthermore, L-DOPA treatment in the DA-
depleted condition of Parkinson’s disease (PD) provides an example where this dystonia-associated pathway pathologically activates mTOR and associated protein
translation machinery via DARPP-32, ERK1/2, and the striatum-specific Rhes G protein [61,62,64]. Additional abbreviations: 4EBP1, eukaryotic translation initiation factor 4E-
binding protein 2 (EIF4EBP1); S6, ribosomal protein S6; S6K, S6 kinase. (B) Gnal encodes the stimulatory heterotrimeric G protein a-subunit expressed by most striatal
neurons. Images of Gnas and Gnal expression in the mouse cortex, striatum, and cerebellum are from the Allen Mouse Brain Atlas [68]. In situ hybridization signals for Gnas
mRNA (left panels: http://mouse.brain-map.org/experiment/show/510) are seen in the majority of cortical and cerebellar neurons, but are present in only a small subset of
striatal neurons that are probably cholinergic interneurons [29]. By contrast, Gnal in situ hybridization signals (right panels: http://mouse.brain-map.org/experiment/show/
69734482) are clearly detected in the majority of striatal neurons and are stronger than in other brain areas.
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neurons are specifically dependent on GNAL/Ga(olf) for
GPCR stimulation of cAMP levels because they lack
GNAS/Ga(s) [27,30]. Furthermore, functional analyses sug-
gest that dystonia-causing mutations suppress Ga(olf) ac-
tivity [22] and the association between GNAL mutations
and dystonia has been confirmed by independent laborato-
ries and in different ethnic backgrounds [23]. Thus, these
data provide strong evidence that GNAL-associated prima-
ry dystonia develops because of impaired striatal signal
transduction.
The striatum is the input station for basal ganglia
movement processing
A consideration of striatal neuron connectivity and phar-
macology is needed to translate how GCH1, TH, or GNAL
mutations affect CNS function and cause dystonia. Thestriatum filters a massive cortical and thalamic excitatory
glutamatergic signal into an inhibitory GABAergic output
that ultimately determines movement/action (Figure 2).
The striatum is also the site where DA release promotes
movement by signaling to striatal neurons. The majority of
striatal neurons are medium spiny neurons (MSN) that
project to basal ganglia output nuclei. There are two
categories of MSN: the ‘direct pathway’ MSN that project
to the substantia nigra pars reticulata/internal globus
pallidus (entopeduncular nucleus of rodents), and the
MSN forming the ‘indirect pathway’ that project to the
external globus pallidus (globus pallidus of rodents)
[31,32]. Pioneering studies determined that direct path-
way MSN express high levels of the D1 DA receptor gene
(D1DR), whereas expression of both D2DR and adenosine 2
receptors (A2AR) is the hallmark of MSN of the indirect
pathway [33,34]. The striatum also contains several719
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Figure 2. Microcircuitry of the striatum. The striatum is the input nucleus of the basal ganglia motor circuit and integrates glutamatergic (Glut) inputs from the cortex and
thalamus (Thal). The striatum contains at least six distinct classes of neuron. The majority are GABAergic medium spiny neurons (MSN) that send axons to basal ganglia
output nuclei. MSN are traditionally subdivided in terms of their projection patterns and neuropeptide and dopamine (DA) receptor expression profiles. Direct pathway
MSN project to the substantia nigra pars reticulata, predominantly express D1DR receptors (D1), and promote directed movement, whereas indirect pathway neurons
project to the globus pallidus, predominantly express receptors D2DR (D2) and A2AR (adenosine 2 receptor; A2A), and their activity appears to suppress the drive to
movement [69]. The striatum also contains several classes of interneuron. There are at least three distinct types of GABAergic interneurons: fast-spiking (FS) parvalbumin
(PV)-expressing interneurons, interneurons expressing calreticulin (CR-I), and a class of neurons that coexpress neuropeptide Y (NPY), NOS (nitric oxide synthase), and
somatostatin (SS). There are also giant interneurons that release acetylcholine (ChI). DA is released in the striatum from axon terminals that originate in the substantia nigra
pars compacta (SNpc). DA is a centrally-important modulator of striatal neuron activity via a complex series of events mediated by receptors present on the presynaptic
terminals of striatal inputs, on striatal projection neurons and on striatal interneurons. Notably, although excitatory D5DRs (D5, yellow) are expressed at low levels, they are
present on many striatal neurons and are higher-affinity DA receptors [70], thus further complicating simple predictions for how DA modifies the activity of different striatal
neuron subtypes [36].
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tors, as well as DA-sensitive cholinergic interneurons that
output rhythmic acetylcholine release and also modulate
DA levels. Thus, a complex mix of glutamate, adenosine,
DA, acetylcholine, GABA, and several neuropeptides, mod-
ify striatal control of movement [35,36] (Figure 2). The
complexity of this neuronal circuitry is a major challenge
for a unifying theory of striatal function and neurotrans-
mitter actions. However, it is clear that striatal DA720promotes movement, as classically evidenced by the
bradykinesia produced when DA neurons degenerate in
Parkinson’s disease (PD), whereas degeneration of striatal
neurons, with a preference for indirect MSN loss, drives
the hyperkinetic motor disturbance of Huntington’s
disease.
DA receptors are subdivided into two groups: ‘excitato-
ry’ D1DR-like, comprising the D1DR and D5DR proteins,
and ‘inhibitory’ D2DR-like including the products of the
Box 1. DA receptor-blocking drugs and dystonia
Hyperkinetic movement disorders, including dystonia, can appear
as a side effect of different psychoactive drugs, including commonly
prescribed compounds such as haloperidol. These side effects are
most strongly associated with first-generation neuroleptics that
competitively block D2DRs. Most D2DR antagonist drug-induced
dystonia occurs relatively early in the course of treatment and is
reversible on drug discontinuation. However, abnormal involuntary
movements also appear after chronic D2DR antagonist use,
particularly in the elderly. These motor dysfunctions are often
irreversible and difficult to treat, suggesting that long-term D2DR
blockade induces permanent changes in striatal physiology. The
affinity of the antagonists for D2DR is considered relevant for the
drug to bear neuroleptic potential. Of interest, positron emission
tomography (PET) studies have shown that optimal antipsychotic
response requires approximately 60% D2DR occupancy; higher
occupancy rates are also associated with increased incidence of
motor side effects [71–73]. Nevertheless, the appearance of dystonia
is variable and only some individuals develop side effects from
D2DR blockade. Thus, drug-induced dystonia is another situation
where a dystonia-causing insult is well defined, but other modifiers
appear to affect the ‘penetrance’ of dystonia development.
Overall, there is little mechanistic understanding of how D2DR
antagonists cause hyperkinetic movements. There is no strong or
single-locus genetic explanation for the variability in the occurrence
of drug-induced dystonia, although associations are found with
polymorphisms in the D2DR gene and in genes encoding the GRIN1
and 2A subunits of the NMDA receptor and the D1DR (reviewed by
Teo et al. [74]). Furthermore, the precise involvement of the different
D2DR-like receptor subtypes, encoded by the D2DR, D3DR and D4DR
genes, remains uncertain, and other neurotransmitters and NMDA
and 5-HT receptors emerge as possible alternatives [74]. It seems
likely that different mechanisms account for reversible versus
irreversible forms of drug-induced dystonia that result from acute
and chronic drug administration, respectively. For irreversible drug-
induced dystonia it is also necessary to consider how long-term use
of D2DR antagonists permanently alters striatal physiology and
neurotransmission because there is no obvious sign of structural
defects in these patients. The idea that long-term neuroleptic use
induces maladaptive synaptic plasticity has been proposed [74] but,
in general, we are some distance from understanding the molecular
details of how pharmacological repression of DA signaling perma-
nently affects the striatum and motor circuitry.
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The different classes of DA receptor couple to different G
proteins, and thus DA has different effects depending on
which receptors are present (Figure 1A). In a traditional
model of basal ganglia function, the direct pathway MSN
facilitates movement whereas activation of indirect path-
way MSN represses movement. This model also postulates
that DA differentially modulates these pathways by stim-
ulating, via the excitatory D1DR, direct pathway MSN and
suppressing the indirect pathway MSN (via the D2DR).
However, the picture is more complex than represented by
this model. For example, there is presynaptic expression of
D2DR on DA and glutamatergic terminals. Furthermore,
the high-affinity D5DR is expressed by both types of MSN
and striatal interneurons [35,36], and there is evidence for
coexpression of D1DR and D2DR genes in a subset of MSN
projection neurons [37–39] (Figures 1A,2). There are also
other neurotransmitter receptors that signal into DA-sen-
sitive signal transduction cascades, most notably the stria-
tal A2AR that couple to GNAL/Ga(olf) and cAMP
production, and can heterodimerize with D2DR [40]
(Figure 1A). In addition, alongside the model of direct
and indirect pathway competition, there is emerging evi-
dence for coordinated activation of both MSN pathways
during movement [41,42].
Suppression of a striatal GCH1, TH, and GNAL
molecular pathway leads to dystonia
The GCH1, TH, and GNAL dystonia genes are components
of a striatal DA signaling pathway (Figure 1A). GCH1 and
TH gene products participate in DA synthesis in the
presynaptic portion of this pathway. This biochemical role
and the conclusion that impaired DA synthesis causes
dystonia derives from the fact that DRD-causing muta-
tions are typically loss-of-function type mutations, L-DO-
PA administration effectively remediates dystonia
symptoms, and there is a demonstrated DA deficiency
in the striatum of DRD patients [18,43]. GNAL/Ga(olf)
functions immediately downstream of striatal D1DR,
D5DR, and A2AR, and couples these GPCR subtypes to
AC, cAMP, and protein kinase A (PKA) activation [30]
(Figure 1A). There are also data from Gnal mice that
Ga(olf) expression is rate-limiting for DA stimulation of
cAMP [44]. Thus, based on the selective expression, bio-
chemical functions, and the nature of GCH1, TH, and
GNAL mutations, it appears that these three genetic
causes of dystonia intersect to suppress the D1DR-like/
cAMP/PKA pathway in striatal neurons. It is also inter-
esting to consider that individuals with GCH1 and TH
mutations respond well to L-DOPA therapy because this
reverses the fundamental problem of DA deficiency, al-
though L-DOPA is unlikely to be as effective when the
pathway-suppressing mutation lies downstream of DA or
receptors. Together, these data strongly lead to the re-
emergence of ‘old ideas’ on the role of the striatum as a key
player in dystonia pathophysiology.
Evidence for striatal dysfunction in other forms of
dystonia
Numerous lines of evidence link dopaminergic dysfunction
and striatal signaling to the symptom of dystonia [45,46].However, the relationship for primary dystonia remains
contentious because, by definition, primary dystonia is
rarely affected by dopaminergic therapies. The identifica-
tion of GNAL/Ga(olf) as a primary dystonia gene now
highlights the idea that dystonia can occur because of
defects in striatal signal transduction pathways down-
stream of DA receptors. There is also evidence from other
forms of dystonia to support this theory for defective
striatal signaling in dystonia. First, it is well recognized
that short-term and long-term pharmacological blockade of
D2DR produces dystonia. Although the mechanisms un-
derlying this relatively common side effect remain unclear
(Box 1), this further associates dystonia with DA and
striatal dysfunction. Furthermore, striatal D2DR avail-
ability is decreased in THAP1 dystonia and TOR1A dysto-
nia patients, which are two forms of primary dystonia that
rarely respond to DA drugs [47,48]. The deficiency in D2DR
is also seen in non-manifesting carriers of the TOR1A
mutation, which suggests that these DA receptor deficits
are a primary consequence of the dystonia-causing muta-
tion rather than secondary compensation against dystonia.
More evidence for defective DA signaling comes from sev-
eral genetic rodent models of TOR1A dystonia. Mice721
Box 2. mTOR signaling and plasticity
Mechanistic target of rapamycin (mTOR; previously mammalian
TOR) was initially identified as the target of the rapamycin toxin that
inhibits protein synthesis. mTOR is a ubiquitous and a centrally
important regulator of protein synthesis and cell growth. The
pathway is sensitive to many external and internal cues, and is
regarded as a master integrator of signal transduction cascades.
Signals such as the phosphoinositol-3-kinase (PI3K)/Akt pathway or
extracellular signal-regulated kinase (ERK) typically converge on the
upstream tuberous sclerosis complex proteins (TSC) that act as a
GAP (GTPase activating protein) to inactivate the atypical G protein,
Rheb, and activate mTOR. mTOR itself is an atypical serine/
threonine kinase, and the activated mTOR kinase operates within
mTORC1 or mTORC2 complexes to phosphorylate effectors of
mTOR signaling. The best-characterized downstream effect of
mTOR activation is mTORC1 phosphorylation of the p70 ribosomal
protein S6 kinase, which in turn activates S6 and eIF4E-binding
protein 1 (EIF4EBP) to upregulate translation initiation factor activity
and protein synthesis [75].
mTOR in the brain is central to how neurons produce long-term
durable changes in synaptic strength that depend on new protein
synthesis [65,75,76]. mTORC1 pathway components are detected at
postsynaptic terminals; mTORC1 inhibition by rapamycin inhibits
long-term synaptic plasticity in response to electrical or chemical
stimulation and impairs long-term memory formation in animals.
Conversely, mTORC1 stimulation is associated with dendritic spine
formation and synaptogenesis [77]. However, mTORC1 signaling is
not only associated with beneficial physiology. TSC1/2 mutations
that elevate mTOR pathway activity cause autism and intellectual
disability in tuberous sclerosis and, in general, excess mTOR
signaling is associated with pathological aberrant and hyperactive
circuit connectivity [78].
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responses that are paralleled by reduced D2DR protein
levels and impaired activation of the cognate G proteins
[49]. There is also a significant impairment of striatal
neuron plasticity to cortical inputs in transgenic mice
and rats overexpressing mutant torsinA [50,51], as well
as in mice where the dystonia-causing deletion is intro-
duced into the mouse Tor1a gene (DYT1 Dgag knock-in
mice) [52]. Plasticity defects in DYT1 models are primarily
caused by altered D2DR-mediated control of cholinergic
neuron function, and in one model were restored by antag-
onism of A2AR [49,51].
The mechanism(s) that link TOR1A and THAP1 muta-
tions with postsynaptic striatal neurobiological defects are
largely unknown. However, evidence from mouse and Dro-
sophila suggests that torsinA is important for trafficking
postsynaptic mRNAs from the nucleus to the cytosol [53,54].
Furthermore, there is a genetic interaction reported be-
tween Drosophila torsin and DA synthesis [55]. In the case
of THAP1 dystonia, the THAP1 protein is a binding partner
for Par4, which in turn is an interaction partner of the D2DR
[56,57]. Thus, both TOR1A and THAP1 dystonia are associ-
ated with defective postsynaptic striatal responses to DA,
although the evidence points to the D2DR pathway also
implicated in drug-induced dystonias (Box 1) rather than
the D1DR-like pathway at the intersection of TH, GCH1,
and GNAL gene mutations (Figure 1).
Depressed striatal DA signaling leads to dystonia?
There is a paradox if we consider that suppressed striatal
DA signaling causes dystonia, whereas loss of striatal DA
in PD instead decreases the drive for voluntary move-
ments and results in bradykinesia. The need to account
for additional complexity is also highlighted by the strong
relationship between dystonia development and D2DR
blockade (Box 1), whereas GCH1, TH, and GNAL muta-
tions intersect to affect the D1DR-like pathway. There are
no clear explanations for these paradoxes, although the
dual nature of dystonia-causing insults is more consistent
with basal ganglia models that focus on coordinated MSN
activation [42], rather than competition between direct
and indirect pathways, given that this predicts that the
dystonia-causing insults should oppositely affect move-
ment. Furthermore, compensatory interactions within the
striatal microcircuitry or crosstalk between signal trans-
duction cascades, via mechanisms such as dimerization
between A2AR, D1DR, or D2DR proteins [40,58], are one
possibility. One other factor to consider is that familial
dystonia patients are haploinsufficient rather than null
for DA signaling components, and this may induce differ-
ent compensation than stronger, broader blockade from
progressive dopaminergic degeneration in PD. In addi-
tion, a developmental component seems likely. Patients
with familial dystonia have congenitally blunted DA sig-
naling during childhood acquisition of motor skills when
striatal responses may be more plastic than in the case of
an adult who develops PD. This theory of age-associated
differences in how DA loss affects the striatum and move-
ment is also supported by the more frequent appearance of
dystonia in early-onset compared with late-onset forms of
PD [59].722Downstream effects of DA signaling; what is learnt from
L-DOPA dyskinesia
This evidence for a complex interplay of compensations in
the striatum also highlights that there is more to consider
than the top end of striatal signaling to cAMP and PKA
(Figure 1A). Furthermore, the downstream elements of DA
signaling are implicated in LID, another pathological con-
dition with abnormal hyperkinetic movements. L-DOPA is
a DA replacement therapy that compensates for DA loss in
PD and is an important symptomatic treatment for PD
patients. However, the clinical response to L-DOPA
decreases with disease progression, and patients progres-
sively require increasing L-DOPA doses to maintain ther-
apeutic benefit. Ultimately, L-DOPA fails to stably control
motor symptoms and patients exhibit severe fluctuations
in motor activity. LIDs are the most common manifesta-
tions of motor fluctuations, although dystonia can also
become a major complication [60].
Many neurochemical defects exist in the sensitized
striatum of patients and animal models with LID. Howev-
er, hypersensitivity of the D1DR pathway appears to play a
central role, and L-DOPA treatment in LID models causes
dramatic hyperactivation of D1DR pathway components
alongside abnormal movements [60]. There are normal
levels of D1DR in LID models, but D1DR activation
induces hyperphosphorylation of DARPP-32 (dopamine
cAMP regulated phosphoprotein 32 kDa; Figure 1A) and
other PKA targets. DARPP-32 seems to be an important
player in LID and is a phosphatase inhibitor that aug-
ments activation of the ERK1 and ERK2 members of the
MAPK family (mitogen-activated protein kinases) that
alter gene transcription [61]. mTORC1 signaling (Box 2)
Box 3. Outstanding questions
 What are the molecular and physiological consequences of mTOR
activation in striatal MSN?
 Is hyperactive mTOR also a feature of D1DR pathway-associated
dystonia or other dystonias?
 How does suppression or fluctuation of DA signaling in LID/PD
hyperactivate the D1DR pathway and cause pathological coupling
to mTOR signaling?
 Is there a relationship between how dystonia is caused by
pharmacological D2DR blockade or genetic loss of D1DR-like
pathway components?
Review Trends in Neurosciences December 2013, Vol. 36, No. 12is also strongly associated with DARRP-32 hyperactivation
and with how long-term depletion or fluctuations in stria-
tal DA induce pathogenic reprogramming of a DA signal
transduction cascade and LID. This evidence for mTOR
involvement in LID derives from the observation that L-
DOPA treatment strongly induces mTOR activation in
D1dr gene-expressing MSN of the DA-depleted rodent
striatum. By contrast, L-DOPA does not induce mTOR
activation in the normal striatal environment, and thus
it appears that DA receptor coupling to striatal mTOR
activation is a specific response that occurs with suppres-
sion of DA signaling [62]. Furthermore, the mTORC1
inhibitor, rapamycin, suppresses abnormal mTORC1 acti-
vation and dyskinesia-type behaviors in mouse and rat
models [62,63]. This pathogenic coupling of D1DR signal
transduction to mTORC1 occurs via DARPP-32 [61],
hyperactivation of ERK1, ERK2, and Rhes, a striatal-
specific mTOR activating protein that is homologous to
the ubiquitously expressed Rheb [64] (Figure 1A, Box 2).
Thus, research on models of LID has determined that DA
loss can remodel D1DR-like signaling to inappropriately
activate mTOR, which is an effector regarded as being
centrally important for long-term changes in synaptic
plasticity (Box 2). These data provide an intriguing hy-
pothesis for how TH mutations and GCH1 or GNAL hap-
loinsufficiency might affect striatal plasticity and cause
dystonia. Outstanding questions are listed in Box 3.
Concluding remarks
The identification of dystonia-causing genetic mutations is
continuing to lead the way in understanding the molecular
and neurobiological drivers of primary dystonia. There is
an emerging theme where multiple dystonia-causing
mutations converge to affect striatal signaling and signal
transduction pathways similarly. They also suggest a pre-
viously unrecognized relationship between DRD and pri-
mary dystonia. This is an important insight because it
suggests that a focus on how congenital DA deficiency
affects striatal development and plasticity may have gen-
eral importance for understanding primary dystonia. It
will also be fascinating to determine whether primary
dystonia is associated with pathogenic activation of mTOR
signaling that is already implicated in LID. The mTORC1
molecular mechanism is a ‘shoe’ that fits the predictions
and expectations for the mechanisms underlying dystonia:
it is modulated in the striatum by DA pathways and
downstream of verified dystonia genes, it is a master
regulator that integrates cellular homeostasis with envi-
ronment cues, it is an important mediator of synapticplasticity, and mTOR hyperactivation is a known patho-
genic event in the development of functional CNS disease
[65,66]. Pharmacological manipulation of mTOR is cur-
rently under trial for genetically defined autism spectrum
disorders. Potentially, therapies designed for these condi-
tions could be repositioned for LID and may be appropriate
for other hyperkinetic movement disorders. Furthermore,
Rhes and Ga(olf) are relatively specific striatal signal
transduction proteins implicated in GCH1/TH/GNAL dys-
tonia and LIDs. The striatal specific expression raises the
possibility that it may be possible to therapeutically target
striatal dysfunction without generally disturbing CNS
signal transduction. Furthermore, the discovery of special-
ized striatal signal transduction molecules that appear to
couple to synaptic plasticity can reconcile how dystonia can
specifically affect movement while sparing cognitive and
affective circuits.
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